Prostate Cancer
Tackling metastatic prostate cancer through ALDH1A3 inhibition to enhance treatment efficacy and reduce drug resistance.
Colorectal Cancer
Offering precision therapies to patients with advanced colorectal cancer, focusing on reducing recurrence rates.
Lung Cancer
Addressing chemotherapy-resistant non-small cell lung cancers by inhibiting ALDH1A3-driven tumor progression.
Breast Cancer
Targeting aggressive forms of breast cancer with high ALDH1A3 expression to reduce metastasis and improve survival outcomes.
Therapy Resistance
Reduces the efficacy of cancer treatments by limiting their capacity to eliminate resilient tumor cells, hindering recovery.
Tumor Progression
Accounts for over 90% of global cancer deaths, driven by the aggressive spread of secondary tumors to distant organs.